A Phase I/II National, Open-Label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2013
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine; Fludarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Dec 2008 New trial record.